Evrysdi is the only non-invasive disease-modifying SMA treatment and is approved in over 100 countries
The company will showcase groundbreaking innovations from its Pharma and Nutrition divisions, highlighting key ingredients and formulations designed to support holistic well-being
The inspection was carried out from January 28 to February 1, 2025
Teriflunomide is a novel disease-modifying agent that was approved for use in the treatment of multiple sclerosis
The company is committed to unlocking new frontiers in neuroscience and developing Usnoflast for patients with ALS
Olanzapine is indicated for the acute and maintenance treatment of schizophrenia and related psychotic disorders
This study will enrol 210 ALS patients and study doses of 50 mg and 75 mg Usnoflast versus placebo
Jubilant Cadista will submit an appropriate action plan to the USFDA on these observations
Regulatory filings underway for a third indication for darolutamide in prostate cancer, for finerenone in a common form of heart failure, and acoramidis in transthyretin amyloid
Dr. Smith brings 30 years of clinical and translational research experience in obesity, diabetes, and metabolism with over 300 scientific publications
Subscribe To Our Newsletter & Stay Updated
